Needham analyst Gil Blum maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today and set a price target of $42.00.
Gil Blum has given his Buy rating due to a combination of factors that highlight Rocket Pharmaceuticals’ strategic positioning and potential for growth. The company’s reliance on US-based inputs and its commercial and clinical AAV manufacturing in Cranbury, NJ, suggest a stable supply chain with minimal exposure to international tariffs, which is a positive indicator for operational stability.
Additionally, Rocket Pharmaceuticals has established agreements on pivotal study designs for its key programs in DD and PKD, which were in place before changes in regulatory leadership. The company’s ongoing communication with the broader team at CBER further supports its commitment to advancing genetic medicines, indicating a strong regulatory pathway. These elements combined suggest a promising outlook for Rocket Pharmaceuticals, justifying the Buy rating.
According to TipRanks, Blum is an analyst with an average return of -17.5% and a 27.02% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Cartesian Therapeutics, and Geron.
In another report released yesterday, BMO Capital also reiterated a Buy rating on the stock with a $50.00 price target.